Principles of adoptive T cell therapy in cancer

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Principles of adoptive T cell therapy in cancer. / Met, Özcan; Jensen, Kasper Mølgaard; Chamberlain, Christopher Aled; Donia, Marco; Svane, Inge Marie.

In: Seminars in Immunopathology, Vol. 41, No. 1, 11.01.2019, p. 49–58.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Met, Ö, Jensen, KM, Chamberlain, CA, Donia, M & Svane, IM 2019, 'Principles of adoptive T cell therapy in cancer', Seminars in Immunopathology, vol. 41, no. 1, pp. 49–58. https://doi.org/10.1007/s00281-018-0703-z

APA

Met, Ö., Jensen, K. M., Chamberlain, C. A., Donia, M., & Svane, I. M. (2019). Principles of adoptive T cell therapy in cancer. Seminars in Immunopathology, 41(1), 49–58. https://doi.org/10.1007/s00281-018-0703-z

Vancouver

Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Principles of adoptive T cell therapy in cancer. Seminars in Immunopathology. 2019 Jan 11;41(1):49–58. https://doi.org/10.1007/s00281-018-0703-z

Author

Met, Özcan ; Jensen, Kasper Mølgaard ; Chamberlain, Christopher Aled ; Donia, Marco ; Svane, Inge Marie. / Principles of adoptive T cell therapy in cancer. In: Seminars in Immunopathology. 2019 ; Vol. 41, No. 1. pp. 49–58.

Bibtex

@article{e122ea5fd7c64fa2a2aac62ee58b602e,

title = "Principles of adoptive T cell therapy in cancer",

abstract = "Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers. Many ACT-based therapies have recently entered late-phase clinical testing, with several T cell therapies already achieving regulatory approval for the treatment of patients with B cell malignancies. In this review, we briefly outline the principles of adoptively transferred T cells for the treatment of cancer.",

keywords = "Adoptive cell therapy, Cancer immunotherapy, Chimeric antigen receptor, T cells, Tumor-infiltrating lymphocytes",

author = "{\"O}zcan Met and Jensen, {Kasper M{\o}lgaard} and Chamberlain, {Christopher Aled} and Marco Donia and Svane, {Inge Marie}",

year = "2019",

month = jan,

day = "11",

doi = "10.1007/s00281-018-0703-z",

language = "English",

volume = "41",

pages = "49–58",

journal = "Seminars in Immunopathology",

issn = "1863-2297",

publisher = "Springer",

number = "1",

}

RIS

TY - JOUR

T1 - Principles of adoptive T cell therapy in cancer

AU - Met, Özcan

AU - Jensen, Kasper Mølgaard

AU - Chamberlain, Christopher Aled

AU - Donia, Marco

AU - Svane, Inge Marie

PY - 2019/1/11

Y1 - 2019/1/11

N2 - Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers. Many ACT-based therapies have recently entered late-phase clinical testing, with several T cell therapies already achieving regulatory approval for the treatment of patients with B cell malignancies. In this review, we briefly outline the principles of adoptively transferred T cells for the treatment of cancer.

AB - Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers. Many ACT-based therapies have recently entered late-phase clinical testing, with several T cell therapies already achieving regulatory approval for the treatment of patients with B cell malignancies. In this review, we briefly outline the principles of adoptively transferred T cells for the treatment of cancer.

KW - Adoptive cell therapy

KW - Cancer immunotherapy

KW - Chimeric antigen receptor

KW - T cells

KW - Tumor-infiltrating lymphocytes

U2 - 10.1007/s00281-018-0703-z

DO - 10.1007/s00281-018-0703-z

M3 - Journal article

C2 - 30187086

AN - SCOPUS:85053396565

VL - 41

SP - 49

EP - 58

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

SN - 1863-2297

IS - 1

ER -

ID: 208885873